CCIA
IBRX icon

Cherry Creek Investment Advisors’s ImmunityBio IBRX Stock Holding History

Cherry Creek Investment Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$718K Buy
76,088
+1,407
+2% +$11.2K 0.28% 58
2026
Q2 		$654K Buy
74,681
+100
+0.1% +$757 0.26% 61
2026
Q1 		$572K Buy
74,581
+60,653
+435% +$415K 0.25% 63
2025
Q4 		$27.6K Buy
+13,928
New +$31.6K 0.01% 117

Other funds holding IBRX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
MWM
MFG Wealth Management Indianapolis, Indiana $138M AUM 31.54% 1-Year Est. Return
CFO
Collective Family Office York, Pennsylvania $484M AUM 13.93% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $532M AUM 15.78% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $546M AUM 14.96% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return
FWP
Firethorn Wealth Partners Augusta, Georgia $313M AUM 15.55% 1-Year Est. Return

Cherry Creek Investment Advisors's IBRX Position: Q3 2026 in Review

Cherry Creek Investment Advisors increased its ImmunityBio (IBRX) stake by 1.9% in Q3 2026, buying an estimated $11.2K and bringing the position to 76,088 shares worth $718K. The position accounts for 0.28% of the portfolio, ranked #58.

Cherry Creek Investment Advisors first reported a position in IBRX in Q4 2025 and has held it in 4 quarters since. 29 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Cherry Creek Investment Advisors held 76,088 shares of ImmunityBio worth $718K as of Q3 2026.
  • Cherry Creek Investment Advisors bought 1,407 ImmunityBio shares in Q3 2026, an estimated $11.2K.
  • ImmunityBio made up 0.28% of Cherry Creek Investment Advisors's portfolio in Q3 2026, its #58 holding.
  • Cherry Creek Investment Advisors first reported a position in ImmunityBio in Q4 2025 and has held it in 4 quarters since.
  • 29 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Cherry Creek Investment Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.